531686 ADVIKLA

MPS Pharma Share Price

 

 

Start SIP in ADVIKLA

Start SIP

Performance

  • Low
  • ₹2
  • High
  • ₹2
  • 52 Week Low
  • ₹2
  • 52 Week High
  • ₹4
  • Open Price₹2
  • Previous Close₹2
  • Volume1
  • 50 DMA₹2.41
  • 100 DMA₹2.63
  • 200 DMA₹2.48

Investment Returns

  • Over 1 Month -4.55%
  • Over 3 Month -11.58%
  • Over 6 Month -30%
  • Over 1 Year -59.81%

Smart Investing Starts Here Start SIP with MPS Pharma for Steady Growth!

Invest Now

MPS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -3.4
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 3
  • P/B Ratio
  • 5
  • Average True Range
  • 0.08
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.26
  • RSI
  • 23.98
  • MFI
  • 17.05

MPS Pharma Financials

MPS Pharma Technicals

EMA & SMA

Current Price
₹1.68
0 (0%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1.95
  • 50 Day
  • ₹2.41
  • 100 Day
  • ₹2.63
  • 200 Day
  • ₹2.48

Resistance and Support

1.68 Pivot Speed
  • R3 1.68
  • R2 1.68
  • R1 1.68
  • S1 1.68
  • S2 1.68
  • S3 1.68

MPS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-02 Quarterly Results
2025-11-14 Quarterly Results
2025-09-02 A.G.M.
2025-08-12 Quarterly Results
2025-05-28 Audited Results

MPS Pharma F&O

MPS Pharma Shareholding Pattern

35.89%
37.12%
26.99%

About MPS Pharma

  • NSE Symbol
  • ADVIKLA
  • BSE Symbol
  • 531686
  • Managing Director
  • Mr. Peeyush Kumar Aggarwal
  • ISIN
  • INE537C01019

Similar Stocks to MPS Pharma

MPS Pharma FAQs

MPS Pharma share price is ₹1 As on 09 February, 2026 | 00:24

The Market Cap of MPS Pharma is ₹3.2 Cr As on 09 February, 2026 | 00:24

The P/E ratio of MPS Pharma is -3.4 As on 09 February, 2026 | 00:24

The PB ratio of MPS Pharma is 5 As on 09 February, 2026 | 00:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23